Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Advancell Pty Limited currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This case is assigned to examiner Melissa Jean Perreira, who is the only examiner currently reviewing a pending action for the company. The prosecution is taking place within 1 distinct art unit, which limits the technical review to a specific specialized group. Melissa Jean Perreira is also designated as the busiest examiner for the company.
This profile represents a highly focused and singular prosecution effort. The outcome of the company's current pending portfolio is dependent on the interaction with this specific examiner and the standards of the assigned art unit. Practitioners should be aware that the entire pending workload is concentrated in this single matter. This lack of distribution means that there are no other pending cases to provide broader context for the company's prosecution history in this technology area. The pending action must be managed with a high degree of attention to the specific preferences of the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERREIRA, MELISSA JEAN | 1 | 52.1% | +25.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19545906 | DOSAGE REGIMEN FOR SHORT-LIVED RADIOISOTOPE | PERREIRA, MELISSA JEAN | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19545906 | DOSAGE REGIMEN FOR SHORT-LIVED RADIOISOTOPE | PERREIRA, MELISSA JEAN | 1618 | §103DP | Non-Final OA | — | Pending | Feb 20, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAdvancell Pty Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Melissa Jean Perreira has the most, with 1 of Advancell Pty Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
